Cannabidiol - bsCBD

Phase 2Small molecule

UUniversity of Colorado, Boulder

Cannabidiol - bsCBD is one of 5 small molecule programs targeting Cannabis Use Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cannabis Use DisorderRecruiting

Cannabis Use DisorderPhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Cannabis Use Disorder

#DrugCompanyPhaseTrials

Mounjaro

Eli Lilly

Phase 2

2 2

Dayvigo

Eisai

Preclinical

1 3

Psilocybin

COMPASS Pathways

Phase 1

1 4

Cannabidiol - bsCBD

UUniversity of Colorado, Boulder

Phase 2

1 5

Pregnenolone

VVA Office of Research and Development

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Recruiting

Cannabis Use Disorder

NCT06107062

Clinical

Trials by Indication[1]

Cannabis Use Disorder1 trial

Longitudinal Outpatient Treatment for Cannabis Use Disorder

Recruiting·UUniversity of Colorado, Boulder·Phase 2·NCT06107062·165 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cannabidiol - bsCBD. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cannabidiol - bsCBD compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cannabidiol - bsCBD. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Colorado, Boulder company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Colorado, Boulder

Cannabidiol - bsCBD

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Trials by Indication[1]

Cannabis Use Disorder1 trial

References

Drug Info

Quick Facts

Related News